首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1890927

基因靜默市場：按類型、按組件、按應用、按治療領域、按技術、按給藥方式、按最終用戶、按地區分類

Gene Silencing Market, By Type, By Component, By Application, By Therapeutic Area, By Technology, By Delivery Method, By End User, By Geography

出版日期: 2025年11月18日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

基因靜默市場預計在 2025 年達到 112.1 億美元，預計到 2032 年將達到 278.8 億美元，2025 年至 2032 年的複合年成長率為 13.9%。

報告覆蓋範圍		報告詳情
基準年：	2024	2025年市場規模：	112.1億美元
歷史數據時期：	2020年至2024年	預測期：	2025年至2032年
預測期（2025-2032年）複合年成長率：	13.90%	2032 年的預測值：	278.8億美元

全球基因靜默市場是生物技術和製藥行業中一個快速發展的領域，涵蓋了靶向和調控特定基因表現的創新治療方法。基因靜默，也稱為RNA干擾（RNAi）或基因敲低，涉及複雜的分子機制，可透過多種調查方法抑製或降低目標基因的表達，包括小干擾RNA（siRNA）、微型RNA （miRNA）、反義寡核苷酸和基於CRISPR的技術。

由於遺傳性疾病、癌症、心血管疾病和神經系統疾病的日益增多，這些疾病都需要精準醫療，因此基因沉默市場正蓬勃發展。這項技術為治療過去難以攻克的疾病提供了前所未有的機遇，它能夠特異性定序致病基因，同時最大限度地減少脫靶效應。主要的製藥、生物技術和研究機構正在大力投資基因靜默平台，以開發下一代療法。該市場涵蓋多種遞送系統，包括脂質奈米顆粒、病毒載體和基於偶聯物的遞送機制，這些系統能夠提高基因靜默劑的穩定性和生物利用度。隨著法規結構的不斷完善和對這些創新治療方法的支持，基因靜默市場預計將在多個治療領域革新治療模式，在全球創造巨大的商業機遇，並滿足尚未滿足的醫療需求。

市場動態

全球基因靜默市場受多種強勁因素驅動。全球遺傳性疾病和慢性疾病的日益普遍，使得針對能夠特異性調控致病基因的標靶治療介入措施的需求顯著成長。越來越多的RNAi療法已通過核准上市，例如patisiran和givosiran，證明了基因靜默技術的臨床潛力，並刺激了整個製藥業的進一步投資和研發活動。遞送系統技術的進步，特別是脂質奈米顆粒和組織特異性標靶化機制，顯著提高了治療效果並降低了副作用，使基因靜默療法更容易臨床應用。然而，該市場也面臨諸多限制因素。這些因素包括基因靜默療法的高昂研發成本、需要專業設施和技術專長的複雜生產流程，以及嚴格的監管要求，這些都會延長研發週期並增加企業的財務風險。

此外，脫靶效應、免疫抗原性問題以及向特定組織的遞送效率等挑戰仍然是廣泛應用的技術障礙。儘管有這些局限性，但隨著應用範圍從罕見疾病擴展到心血管、代謝和腫瘤等更常見的疾病，巨大的機會正在湧現。人們對個人化醫療和精準治療日益成長的興趣為基因靜默技術創造了有利條件。同時，製藥公司和生物技術公司之間日益密切的合作正在促進知識共用並加速產品開發。此外，新興市場隨著醫療基礎設施的完善和創新治療方法監管途徑的建立，蘊藏著巨大的未開發潛力。這為基因靜默市場在各個治療領域實現持續成長和創新鋪平了道路。

本次調查的主要特點

本報告對全球基因靜默市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）內的市場規模（十億美元）和復合年成長率（%）。
它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、阻礙因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
該報告根據以下參數對全球基因靜默市場的主要參與者進行了分析：公司概況、產品系列、主要特徵、財務表現和策略。
本報告的研究結果將使負責人和經營團隊能夠就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
這份全球基因靜默市場報告的目標受眾是該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過各種用於分析全球基因靜默市場的策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第12章競爭格局

Thermo Fisher Scientific Inc.
Merck KGaA
Agilent Technologies Inc.
Danaher Corporation
Bio Rad Laboratories Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Silence Therapeutics plc
Dicerna Pharmaceuticals Inc.
Sarepta Therapeutics Inc.
Arbutus Biopharma Corporation
Wave Life Sciences Ltd.
Moderna Inc.
BioNTech SE

第13章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第14章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8955

Gene Silencing Market is estimated to be valued at USD 11.21 Bn in 2025 and is expected to reach USD 27.88 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 11.21 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	13.90%	2032 Value Projection:	USD 27.88 Bn

The global gene silencing market represents a rapidly evolving segment within the biotechnology and pharmaceutical industries, encompassing innovative therapeutic approaches that target specific genes to modulate their expression. Gene silencing, also known as RNA interference (RNAi) or gene knockdown, involves sophisticated molecular mechanisms that prevent or reduce the expression of target genes through various methodologies including small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, and CRISPR-based technologies.

This market has gained substantial momentum due to increasing prevalence of genetic disorders, cancer, cardiovascular diseases, and neurological conditions that require precision medicine approaches. The technology offers unprecedented opportunities for treating previously undruggable targets by specifically silencing disease-causing genes while minimizing off-target effects. Major pharmaceutical companies, biotechnology firms, and research institutions are heavily investing in gene silencing platforms to develop next-generation therapeutics. The market encompasses various delivery systems including lipid nanoparticles, viral vectors, and conjugate-based delivery mechanisms that enhance the stability and bioavailability of gene silencing agents. As regulatory frameworks continue to evolve and support these innovative therapies, the gene silencing market is positioned to transform treatment paradigms across multiple therapeutic areas, driving significant commercial opportunities and addressing critical unmet medical needs globally.

Market Dynamics

The global gene silencing market is propelled by several compelling drivers, including the escalating prevalence of genetic disorders and chronic diseases worldwide, which creates substantial demand for targeted therapeutic interventions that can specifically modulate disease-causing genes. The increasing success of approved RNAi therapeutics such as patisiran and givosiran has validated the clinical potential of gene silencing technologies, encouraging greater investment and development activities across the pharmaceutical industry. Technological advancements in delivery systems, particularly lipid nanoparticles and tissue-specific targeting mechanisms, have significantly improved the therapeutic efficacy and reduced adverse effects, making gene silencing approaches more viable for clinical applications. However, the market faces notable restraints including high development costs associated with gene silencing therapies, complex manufacturing processes requiring specialized facilities and expertise, and stringent regulatory requirements that extend development timelines and increase financial risks for companies.

Additionally, challenges related to off-target effects, immunogenicity concerns, and delivery efficiency to specific tissues continue to pose technical barriers for widespread adoption. Despite these constraints, substantial opportunities emerge from expanding applications beyond rare diseases into more prevalent conditions such as cardiovascular diseases, metabolic disorders, and oncology indications. The growing emphasis on personalized medicine and precision therapeutics creates favorable conditions for gene silencing technologies, while increasing collaborations between pharmaceutical companies and biotechnology firms facilitate knowledge sharing and accelerate product development. Furthermore, emerging markets present untapped potential as healthcare infrastructure improves and regulatory pathways for innovative therapies become more established, positioning the gene silencing market for sustained growth and innovation across diverse therapeutic landscapes.

Key Features of the Study

This report provides in-depth analysis of the global gene silencing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global gene silencing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Danaher Corporation, Bio Rad Laboratories Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Dicerna Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arbutus Biopharma Corporation, Wave Life Sciences Ltd., Moderna Inc., and BioNTech SE
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global gene silencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gene silencing market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Post-Transcriptional
- Transcriptional
Component Insights (Revenue, USD Bn, 2020 - 2032)
- Product (Reagents, Kits, Instruments)
- Services
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Functional Genomics
- Drug Target Validation
- Disease Modeling
- Therapeutic Development
- Bioproduction Optimization
Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Genetic Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Metabolic Disorders
- Autoimmune Disorders
- Ophthalmic Diseases
Technology Insights (Revenue, USD Bn, 2020 - 2032)
- RNA Interference (RNAi)
- Antisense Oligonucleotides (ASOs)
- CRISPR-based Gene Silencing
- siRNA
- shRNA
- miRNA
- DNA Methylation-based Silencing
- Histone Modification-based Silencing
Delivery Method Insights (Revenue, USD Bn, 2020 - 2032)
- Viral Vector Delivery
- Non-Viral Vector Delivery
- Lipid Nanoparticles
- Electroporation
- Physical Methods (Microinjection, Gene Gun, Ultrasound)
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Pharmaceutical and Biotech Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Diagnostic Laboratories
- Government and Non-Profit Research Bodies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies Inc.
- Danaher Corporation
- Bio Rad Laboratories Inc.
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals Inc.
- Sarepta Therapeutics Inc.
- Arbutus Biopharma Corporation
- Wave Life Sciences Ltd.
- Moderna Inc.
- BioNTech SE

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Gene Silencing Market, By Type
- Global Gene Silencing Market, By Component
- Global Gene Silencing Market, By Application
- Global Gene Silencing Market, By Therapeutic Area
- Global Gene Silencing Market, By Technology
- Global Gene Silencing Market, By Delivery Method
- Global Gene Silencing Market, By End User
- Global Gene Silencing Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Gene Silencing Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Post-Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Gene Silencing Market, By Component, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Product (Reagents, Kits, Instruments)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Gene Silencing Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Functional Genomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Drug Target Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Therapeutic Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bioproduction Optimization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Gene Silencing Market, By Therapeutic Area, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Gene Silencing Market, By Technology, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
RNA Interference (RNAi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Antisense Oligonucleotides (ASOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
CRISPR-based Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
siRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
shRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
miRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
DNA Methylation-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Histone Modification-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Gene Silencing Market, By Delivery Method, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Non-Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lipid Nanoparticles
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Electroporation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Physical Methods (Microinjection, Gene Gun, Ultrasound)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Gene Silencing Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pharmaceutical and Biotech Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Government and Non-Profit Research Bodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Gene Silencing Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Component, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

12. Competitive Landscape

Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Agilent Technologies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bio Rad Laboratories Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alnylam Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ionis Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Arrowhead Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Silence Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Dicerna Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sarepta Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Arbutus Biopharma Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wave Life Sciences Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Moderna Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies